Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF + peginterferon alfa-2a versus TDF or peginterferon alfa-2a alone in chronic hepatitis B
2010-024586-45Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2011
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Chronic Hepatitis B (CHB) comparing TDF + peginterferon alfa-2a, TDF monotherapy and Peginterferon alfa-2a monotherapy (3 arms). Primary endpoint: HBsAg loss at Week 72. Started Mar 2011; status: completed.
02
Drugs
tenofovir disoproxil fumaratepeginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2010-024586-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024586-45.